Co-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation
mTORC1/TORC2抑制剂INK128与Bcl-2/Bcl-xL拮抗剂ABT-737联合给药可通过Mcl-1下调和AKT失活杀死人类髓系白血病细胞。
期刊:Haematologica
影响因子:7.9
doi:10.3324/haematol.2015.130351
Rahmani, Mohamed; Aust, Mandy Mayo; Hawkins, Elisa; Parker, Rebecca E; Ross, Masey; Kmieciak, Maciej; Reshko, Leonid Borisovich; Rizzo, Kathryn A; Dumur, Catherine I; Ferreira-Gonzalez, Andrea; Grant, Steven
Bcl-2
mTOR
NK1
白血病
ORC2
ORC1
细胞生物学
AKT